Physician profile
Silva Markovic-Plese
NPI 1255403747
$37,275.54
in general payments reported to CMS, 2019-2025
14 companies · $221 in 2025
The $221 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,696 · 2021: $961 · 2022: $3,949 · 2023: $10K · 2024: $62.05 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,941 · Consulting Fee: $4,615 · Travel and Lodging: $593 · Food and Beverage: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,941.00 |
| Consulting Fee | $4,614.50 |
| Travel and Lodging | $592.85 |
| Food and Beverage | $351.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $13,896.69 | 2019-2022 | |
| Genzyme Corporation | $11,844.84 | 2019-2023 | |
| Mylan Specialty L.P. | $5,146.18 | 2023 | |
| Genentech USA, INC. | $3,300.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $1,620.00 | 2020 | |
| Tg Therapeutics, INC. | $600.00 | 2021 | |
| Biogen, INC. | $364.44 | 2019-2025 | Tysabri |
| Celgene Corporation | $175.57 | 2021 | |
| Amgen INC. | $132.93 | 2024-2025 | Uplizna |
| Sanofi-Aventis U.S. LLC | $99.00 | 2020 | |
| Genentech, INC. | $49.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.94 | 2020-2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Silva Markovic-Plese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.